Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Ablynx, AbbVie deal

    Ablynx N.V. (Euronext:ABLX), Ghent, Belgium AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Inflammation AbbVie declined to exercise its option to license vobarilizumab (ALX-0061) from Ablynx to treat rheumatoid …

    Published on 10/24/2016
  • Ablynx, Merck deal

    Ablynx N.V. (Euronext:ABLX), Ghent, Belgium Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Antibodies Ablynx said it and partner Merck extended to 2018 a 2012 deal to develop and commercialize Ablynxs …

    Published on 10/24/2016
  • Antegrin, Cascadia deal

    Antegrin Therapeutics LLC, St. Louis, Mo. Cascadia Therapeutics LLC, Seattle, Wash. Business: Pharmaceuticals Antegrin and Cascadia merged to form Indalo Therapeutics Inc. (St. Louis, Mo.). The newco is developing …

    Published on 10/24/2016
  • Apitope, Merck KGaA deal

    Apitope International N.V., Diepenbeek, Belgium Merck KGaA (Xetra:MRK), Darmstadt, Germany Business: Autoimmune Merck returned global rights to multiple sclerosis candidate ATX-MS-1467 to Apitope, terminating the …

    Published on 10/24/2016
  • California Institute for Biomedical Research, Sirenas LLC deal

    California Institute for Biomedical Research, La Jolla, Calif. Sirenas LLC, San Diego, Calif. Business: Neurology, Cancer Sirenas and the institute partnered to discover and develop small molecules in oncology, …

    Published on 10/24/2016
  • Centre for Drug Research and Development, Zucara Therapeutics deal

    Centre for Drug Research and Development, Vancouver, B.C. Zucara Therapeutics Inc., Vancouver, B.C. Business: Endocrine/Metabolic Zucara and the center partnered to develop preclinical somatostatin receptor 2 (SSTR2) …

    Published on 10/24/2016
  • Cerulean, Novartis deal

    Cerulean Pharma Inc. (NASDAQ:CERU), Waltham, Mass. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Cancer Cerulean partnered with Novartis to develop nanoparticle-drug conjugates (NDCs) using Ceruleans …

    Published on 10/24/2016
  • Cynapsus, Sumitomo Dainippon deal

    Cynapsus Therapeutics Inc. (TSX:CTH;NASDAQ:CYNA), Toronto, Ontario Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Business: Neurology Sumitomos Sunovion Pharmaceuticals Inc. unit completed its acquisition…

    Published on 10/24/2016
  • Domain Therapeutics, Mavalon Therapeutics deal

    Domain Therapeutics S.A., Strasbourg, France Mavalon Therapeutics Ltd., Hatfield, U.K. Business: Neurology Domain formed single-asset, U.K.-based newco Mavalon Therapeutics with an investment of up to EUR9 million ($9.9…

    Published on 10/24/2016
  • Emulate, LabCorp deal

    Emulate Inc., Cambridge, Mass. Laboratory Corp. of America Holdings (NYSE:LH), Burlington, N.C. Business: ADMET Emulate and the Covance Inc. contract research unit of LabCorp partnered to develop Emulates Organs-on-…

    Published on 10/24/2016
  • Emulate, University of Southern California deal

    Emulate Inc., Cambridge, Mass. University of Southern California, Los Angeles, Calif. Business: Pharmacogenetics Emulate and the University of Southern California partnered to develop Emulates Organs-on-Chips technology…

    Published on 10/24/2016
  • GlaxoSmithKline, Zai Lab deal

    GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Zai Lab Ltd., Shanghai, China Business: Inflammation GlaxoSmithKline granted Zai exclusive, worldwide rights to two anti-inflammatory candidates targeting multiple …

    Published on 10/24/2016
  • Indiana University Research and Technology, Spotlight Innovation deal

    Indiana University Research and Technology Corp., Indianapolis, Ind. Spotlight Innovation Inc. (OTCQB:STLT), West Des Moines, Iowa Business: Neurology The university granted Spotlight exclusive, worldwide rights to …

    Published on 10/24/2016
  • NBE-Therapeutics, Sotio deal

    NBE-Therapeutics AG, Basel, Switzerland Sotio a.s., Prague, Czech Republic Business: Cancer Sotio and NBE partnered to discover and develop next-generation antibody-drug conjugates (ADCs) against undisclosed targets to …

    Published on 10/24/2016
  • StemImmune, Accurexa deal

    StemImmune Inc., San Diego, Calif. Accurexa Inc. (OTCQX:ACXA), Newark, Del. Business: Cancer, Drug delivery Accurexa and StemImmune partnered to develop stem cell-mediated immunotherapies to treat brain cancer. …

    Published on 10/24/2016
  • TxCell, University of British Columbia deal

    TxCell S.A. (Euronext:TXCL), Valbonne, France University of British Columbia, Vancouver, B.C. Business: Transplant TxCell and the university partnered to develop a CAR-Treg-based immunotherapy to prevent graft rejection…

    Published on 10/24/2016
  • University of Toronto, Advanced Proteome Therapeutics deal

    University of Toronto, Toronto, Ontario Advanced Proteome Therapeutics Corp. (TSX-V:APC;FSE:0E8), Boston, Mass. Business: Cancer, Antibodies The universitys Toronto Recombinant Antibody Centre (TRAC) granted Advanced …

    Published on 10/24/2016
  • UroGen Pharma, Allergan deal

    UroGen Pharma Ltd., Raanana, Israel Allergan plc (NYSE:AGN), Dublin, Ireland Business: Drug delivery UroGen granted Allergan worldwide rights to develop and commercialize its RTGel drug delivery technology for use with …

    Published on 10/24/2016
  • Aslan, Nanyang Technological University deal

    Aslan Pharmaceuticals Ltd., Singapore Nanyang Technological University, Singapore Business: Antibodies Aslan partnered with the university to research and develop Modybodies, which are stabilized heavy chain mAb …

    Published on 10/17/2016
  • AstraZeneca, 3SBio deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. 3SBio Inc. (HKSE:1530), Shenyang, China Business: Endocrine/Metabolic AstraZeneca granted 3SBio exclusive, Chinese rights to commercialize diabetes drugs Byetta exenatide…

    Published on 10/17/2016
  • Aurigene, Curis deal

    Aurigene Discovery Technologies Ltd., Bangalore, India Curis Inc. (NASDAQ:CRIS), Lexington, Mass. Business: Cancer Curis exercised an option from Aurigene to license exclusive, worldwide rights outside India and Russia …

    Published on 10/17/2016
  • Celsion, Childrens National Medical Center, NIH deal

    Celsion Corp. (NASDAQ:CLSN;Tel Aviv:CLSN), Lawrenceville, N.J. Childrens National Medical Center, Washington, D.C. National Institutes of Health, Bethesda, Md. Business: Cancer Celsion, the medical centers Childrens …

    Published on 10/17/2016
  • Clayton Foundation for Research, Renova Therapeutics deal

    Clayton Foundation for Research, Houston, Texas Renova Therapeutics, San Diego, Calif. Business: Cardiovascular Research Development Foundation, the nonprofit supporting organization of The Clayton Foundation, granted …

    Published on 10/17/2016
  • Crescendo Biologics, Takeda deal

    Crescendo Biologics Ltd., Cambridge, U.K. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Cancer Crescendo will use its transgenic mouse platform to discover and optimize Humabodies against …

    Published on 10/17/2016
  • Daiichi Sankyo, Dana-Farber Cancer Institute deal

    Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Dana-Farber Cancer Institute, Boston, Mass. Business: Cancer Daiichi partnered with the institute to develop a translational pharmacology package to treat lung cancer, …

    Published on 10/17/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993